Hydroxyzine: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Pharmacopedia: remove contraindications parameter |
MDElliottMD (talk | contribs) parser-claude: Hydroxyzine MedTemplate refill, Top 300 stub upgrade |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Hydroxyzine (hydrochloride; pamoate salt) | ||
| brand | | brand = Vistaril (pamoate), Atarax (HCl, discontinued in US as brand) | ||
| structure | | structure = | ||
| classes | | classes = [[:Category:Antihistamines|First-generation antihistamine]], [[:Category:Anxiolytics|Anxiolytic]], [[:Category:Antipruritics|Antipruritic]], [[:Category:Sleep aids|Sleep aid (off-label)]] | ||
| | | uses = <vote slug="anxiety-short-term-use">Anxiety symptoms (FDA, short-term)</vote>, <vote slug="pruritus-allergic-use">Pruritus from allergic conditions (FDA)</vote>, <vote slug="preoperative-sedation-use">Preoperative sedation (FDA)</vote>, <vote slug="nausea-vomiting-im-use">Nausea and vomiting (FDA, IM only)</vote>, <vote slug="insomnia-hydroxyzine-use">Insomnia (off-label)</vote>, <vote slug="alcohol-withdrawal-adjunct-use">Acute alcohol withdrawal adjunct (off-label)</vote>, <vote slug="pediatric-agitation-use">Pediatric acute agitation (off-label)</vote> | ||
| uses | | starting_dose = Anxiety: 25-50 mg PO QID. Pruritus: 25 mg PO TID-QID. Insomnia: 25-50 mg PO at bedtime. Pediatric: 50-100 mg/day divided | ||
| starting_dose | | preparations = Tablets 10, 25, 50 mg (HCl); capsules 25, 50, 100 mg (pamoate); oral suspension 25 mg/5 mL; injection 25, 50 mg/mL (IM only, never IV) | ||
| preparations | | fda_max = 400 mg/day theoretical; in practice rarely exceeds 200 mg/day | ||
| fda_max = | | pill_id = | ||
| routes | | routes = Oral, intramuscular | ||
| onset | | onset = 15-30 minutes (oral) | ||
| duration | | duration = 4-6 hours | ||
| halflife | | halflife = 14-25 hours (longer in elderly and hepatic impairment)<ref name="vistaril-label">FDA Prescribing Information, Vistaril (hydroxyzine pamoate), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/011459s045lbl.pdf</ref> | ||
| bioavailability = ~80% (oral)<ref name="vistaril-label" /> | |||
| pregnancy = Limited human data; older agent with substantial use experience; some signal for first-trimester exposure but not conclusive.{{citation needed}} | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful clinical advantage over the benzodiazepine alternatives for short-term anxiety<ref name="vistaril-label" /> | |||
| | | mechanism = <vote slug="hydroxyzine-mech-claim">First-generation H1 histamine receptor antagonist with central nervous system penetration producing sedation. Additional 5-HT2A receptor antagonism, α1-adrenergic antagonism, and anticholinergic effects contribute to the sedative, anxiolytic, and antiemetic activity. Crucially, hydroxyzine has '''no GABA receptor activity''', so it carries no tolerance to anxiolytic effect, no withdrawal syndrome, no dependence liability, and no controlled-substance status, distinguishing it sharply from the benzodiazepine alternatives.</vote> '''QT prolongation''' risk at high doses prompted the FDA's 2015 caution against use in patients with prolonged QT or with concurrent QT-prolonging medicines<ref name="vistaril-label" />. | ||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:Antihistamines]] | |||
[[Category:Anxiolytics]] | [[Category:Anxiolytics]] | ||
[[Category:Antipruritics]] | |||
[[Category:Sleep aids]] | |||